22 research outputs found

    Una nueva << Historia de la Iglesia en Hispanoamérica y Filipinas>>

    Get PDF

    Cien años de teología en América Latina

    Get PDF
    post-print26,16 K

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

    La integración de América en España, antecedente de la comunidad iberoamericana

    No full text

    Teorías franciscanas sobre la evangelización de América en la Edad Moderna

    No full text
    post-print1,49 M

    Iniciativas sociales de los presidentes militares del Ecuador y del Perú

    No full text

    La Comunidad Iberoamericana en el entorno internacional de la Edad Moderna

    No full text

    Luces, sombras y claroscuros en la evangelización hispanoamericana

    No full text
    post-print1,41 M

    Las cumbres iberoamericanas o la actualización de una comunidad histórica

    No full text

    Felipe II, configurador de la Iglesia Hispanoamericana

    No full text
    post-print1,18 M
    corecore